Cite
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).
MLA
Okuma, Yusuke, et al. “Uncommon EGFR Mutations Conducted with Osimertinib in Patients with NSCLC: A Study Protocol of Phase 2 Study (UNICORN/TCOG1901).” Future Oncology (London, England), vol. 18, no. 5, Feb. 2022, pp. 523–31. EBSCOhost, https://doi.org/10.2217/fon-2021-0892.
APA
Okuma, Y., Shimokawa, M., Hashimoto, K., Mizutani, H., Wakui, H., Murakami, S., Atagi, S., Minato, K., Seike, M., Ohe, Y., & Kubota, K. (2022). Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901). Future Oncology (London, England), 18(5), 523–531. https://doi.org/10.2217/fon-2021-0892
Chicago
Okuma, Yusuke, Mototsugu Shimokawa, Kana Hashimoto, Hideaki Mizutani, Hiroshi Wakui, Shuji Murakami, Shinji Atagi, et al. 2022. “Uncommon EGFR Mutations Conducted with Osimertinib in Patients with NSCLC: A Study Protocol of Phase 2 Study (UNICORN/TCOG1901).” Future Oncology (London, England) 18 (5): 523–31. doi:10.2217/fon-2021-0892.